Sign In
Buy ACAD
ACADIA Pharmaceuticals Earnings Calls
| Release date | May 06, 2026 |
| EPS estimate | $0.0400 |
| EPS actual | $0.0200 |
| EPS Surprise | -50.00% |
| Revenue estimate | 280.252M |
| Revenue actual | 268.1M |
| Revenue Surprise | -4.34% |
| Release date | Feb 25, 2026 |
| EPS estimate | $0.137 |
| EPS actual | $1.60 |
| EPS Surprise | 1,067.88% |
| Revenue estimate | 292.787M |
| Revenue actual | 283.989M |
| Revenue Surprise | -3.00% |
| Release date | Nov 05, 2025 |
| EPS estimate | $0.140 |
| EPS actual | $0.260 |
| EPS Surprise | 85.71% |
| Revenue estimate | 292.589M |
| Revenue actual | 278.633M |
| Revenue Surprise | -4.77% |
| Release date | Aug 06, 2025 |
| EPS estimate | $0.140 |
| EPS actual | $0.160 |
| EPS Surprise | 14.29% |
| Revenue estimate | 262.002M |
| Revenue actual | 264.566M |
| Revenue Surprise | 0.98% |
Last 4 Quarters for ACADIA Pharmaceuticals
Below you can see how ACAD performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 06, 2025 |
| Price on release | $23.80 |
| EPS estimate | $0.140 |
| EPS actual | $0.160 |
| EPS surprise | 14.29% |
| Date | Price |
|---|---|
| Jul 31, 2025 | $23.83 |
| Aug 01, 2025 | $23.53 |
| Aug 04, 2025 | $24.04 |
| Aug 05, 2025 | $23.64 |
| Aug 06, 2025 | $23.80 |
| Aug 07, 2025 | $24.40 |
| Aug 08, 2025 | $24.60 |
| Aug 11, 2025 | $24.82 |
| Aug 12, 2025 | $25.45 |
| 4 days before | -0.126% |
| 4 days after | 6.93% |
| On release day | 2.52% |
| Change in period | 6.80% |
| Release date | Nov 05, 2025 |
| Price on release | $22.33 |
| EPS estimate | $0.140 |
| EPS actual | $0.260 |
| EPS surprise | 85.71% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $22.74 |
| Oct 31, 2025 | $22.70 |
| Nov 03, 2025 | $22.37 |
| Nov 04, 2025 | $21.83 |
| Nov 05, 2025 | $22.33 |
| Nov 06, 2025 | $21.65 |
| Nov 07, 2025 | $22.57 |
| Nov 10, 2025 | $22.20 |
| Nov 11, 2025 | $23.72 |
| 4 days before | -1.80% |
| 4 days after | 6.22% |
| On release day | -3.05% |
| Change in period | 4.31% |
| Release date | Feb 25, 2026 |
| Price on release | $24.97 |
| EPS estimate | $0.137 |
| EPS actual | $1.60 |
| EPS surprise | 1,067.88% |
| Date | Price |
|---|---|
| Feb 19, 2026 | $24.33 |
| Feb 20, 2026 | $23.99 |
| Feb 23, 2026 | $24.73 |
| Feb 24, 2026 | $24.59 |
| Feb 25, 2026 | $24.97 |
| Feb 26, 2026 | $24.64 |
| Feb 27, 2026 | $24.56 |
| Mar 02, 2026 | $22.81 |
| Mar 03, 2026 | $22.50 |
| 4 days before | 2.63% |
| 4 days after | -9.89% |
| On release day | -1.32% |
| Change in period | -7.52% |
| Release date | May 06, 2026 |
| Price on release | $21.48 |
| EPS estimate | $0.0400 |
| EPS actual | $0.0200 |
| EPS surprise | -50.00% |
| Date | Price |
|---|---|
| Apr 30, 2026 | $22.45 |
| May 01, 2026 | $21.95 |
| May 04, 2026 | $22.19 |
| May 05, 2026 | $22.35 |
| May 06, 2026 | $21.48 |
| May 07, 2026 | $22.57 |
| May 08, 2026 | $22.40 |
| May 11, 2026 | $21.80 |
| May 12, 2026 | $21.72 |
| 4 days before | -4.32% |
| 4 days after | 1.12% |
| On release day | 5.05% |
| Change in period | -3.25% |
ACADIA Pharmaceuticals Earnings Call Transcript Summary of Q1 2026
ACADIA reported a solid start to 2026 with Q1 total revenue of $268M (adjusted +11% YoY). DAYBUE (trofinetide) delivered $101M (+20% YoY) driven by referral growth, durable patient persistence, and the launch of DAYBUE STIX (powder for oral solution), now broadly available in the U.S. Early STIX uptake is strong (>250 prescriptions through Q1, ~30% treatment‑naive or returning patients) and management believes it will accelerate both new starts and re‑engagement of discontinued patients. NUPLAZID generated $167M (+6% YoY adjusted); referral growth and demand were healthy (referral growth ~11%, demand +8%), though Q1 was modestly impacted by temporary delayed refills that have since normalized. ACADIA reaffirmed 2026 net sales guidance ($1.22B–$1.28B) and expects revenue to be back‑end weighted as expanded salesforce productivity and broader STIX rollout take effect. R&D: the most important near‑term clinical catalysts are the Phase II readout for remlifanserin in Alzheimer’s disease psychosis (ADP) expected Aug–Oct 2026 and an accelerated Japan Phase III readout for trofinetide (Sep–Nov 2026). Management emphasized biomarker‑confirmed AD enrollment for the remlifanserin study to improve regulatory/technical prospects. ACADIA ended Q1 with $851M cash and plans to remain active on BD while prioritizing neurological and rare disease opportunities. R&D head Elizabeth Thompson announced she will retire by year‑end but will remain engaged through the key readouts.
